Budget impact (BI) analysis of cemiplimab-rwlc for advanced basal cell carcinoma (BCC) after hedgehog inhibitor (HHI) therapy in the United States.

被引：0
|
作者：
Paul, Eleanor
Chen, Chieh-I
Chowdhury, Zahra
Xu, Yingxin
Konidaris, Gerasimos
LaFontaine, Patrick R.
Atsou, Kokuvi
Cope, Shannon
Philips, Zoe
Kuznik, Andreas
机构：
[1] Precis HEOR, Vancouver, BC, Canada
[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[3] Sanofi, Reading, Berks, England
[4] Sanofi, Cambridge, MA USA
[5] Sanofi, Chilly Mazarin, France
[6] Z Philips Consulting, Manchester, Lancs, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e18830
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18830
引用
收藏
页数：3
相关论文
共 9 条
  • [1] COST-EFFECTIVENESS OF CEMIPLIMAB IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA (ABCC) WHO PROGRESSED ON OR ARE INTOLERANT TO A HEDGEHOG INHIBITOR (HHI) IN ITALY
    Paul, E.
    LaFontaine, P. R.
    Xu, Y.
    Inocencio, T. J.
    Atsou, K.
    D'Avella, M. C.
    Ader, J.
    Guyot, P.
    Caisip, C.
    Quon, P.
    Chen, C.
    Cope, S.
    VALUE IN HEALTH, 2022, 25 (12) : S161 - S161
  • [2] Phase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy
    Lewis, K. D.
    Fury, M. G.
    Stankevich, E.
    Mathias, M.
    Mohan, K. K.
    Li, S.
    Nunnink, K.
    Perry, C.
    Narwal, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 440 - 440
  • [3] Phase-2-Study of Cemiplimab, a human monoclonal PD-1 Antibody, in Patients with advanced Basal Cell Carcinoma (BCC) who have developed Disease Progression or intolerance with previous Hedgehog Signaling Pathway Inhibitor (HHI) Therapy
    Lewis, K.
    Fury, M.
    Stankevich, E.
    Mathias, M.
    Mohan, K.
    Li, S.
    Nunnink, K.
    Perry, C.
    Narwal, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 40 - 40
  • [4] Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up
    Stratigos, A.
    Sekulic, A.
    Perris, K.
    Bechter, O.
    Prey, S.
    Kaatz, M.
    Lewis, K. D.
    Basset-Sequin, N.
    Chang, A. L. S.
    Dalle, S.
    Orland, A. Fernandez
    Licitra, L.
    Robert, C.
    Ulrich, C.
    Hauschild, A.
    Migden, M. R.
    Dummer, R.
    Yoo, S. Y.
    Coates, E.
    Okoye, E.
    Bowler, T.
    Bassukas, I.
    Loquai, C.
    De Giorgi, V.
    Eroglu, Z.
    Gutzmer, R.
    Ulrich, J.
    Puig, S.
    Seebach, F.
    Fury, M. G.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 38 - 39
  • [5] Primary Analysis of Phase-2-Results for Cemiplimab in Patients (pts) with locally advanced Basal Cell Carcinoma (laBCC) who progress or cannot tolerate Hedgehog Inhibitors (HHI)
    Stratigos, A. J.
    Sekulic, A.
    Peris, K.
    Bechter, O.
    Dutriaux, C.
    Kaatz, M.
    Lewis, K. D.
    Basset-Seguin, N.
    Chang, A. L. S.
    Dalle, S.
    Orland, A. Fernandez
    Licitra, L.
    Robert, C.
    Ulrich, C.
    Hauschild, A.
    Migden, M. R.
    Dummer, R.
    Li, S.
    Bowler, T.
    Fury, M. G.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 41 - 42
  • [6] Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma A Systematic Review and Pooled Analysis of Interventional Studies
    Jacobsen, Audrey A.
    Aldahan, Adam S.
    Hughes, Olivia B.
    Shah, Vidhi V.
    Strasswimmer, John
    JAMA DERMATOLOGY, 2016, 152 (07) : 816 - 824
  • [7] Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up
    Stratigos, Alexander J.
    Sekulic, Aleksandar
    Peris, Ketty
    Bechter, Oliver
    Prey, Sorilla
    Lewis, Karl D.
    Basset-Seguin, Nicole
    Chang, Anne Lynn S.
    Dalle, Stephane
    Orland, Almudena Fernandez
    Licitra, Lisa
    Robert, Caroline
    Ulrich, Claas
    Hauschild, Axel
    Migden, Michael R.
    Dummer, Reinhard
    Yoo, Suk-Young
    Okoye, Emmanuel
    Bassukas, Ioannis
    Loquai, Carmen
    De Giorgi, Vincenzo
    Eroglu, Zeynep
    Gutzmer, Ralf
    Ulrich, Jens
    Puig, Susana
    Inocencio, Timothy J.
    Chen, Chieh-, I
    Lafontaine, Patrick R.
    Seebach, Frank
    Lowy, Israel
    Fury, Matthew G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 90 (02) : 414 - 418
  • [8] Budget impact (BI) analysis of cemiplimab for first-line (1L) advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% in the United States.
    Kuznik, Andreas
    Smare, Caitlin
    Chen, Chieh-I
    Venkatachalam, Meena
    Keeping, Sam
    Atsou, Kokuvi
    Xu, Yingxin
    Wilson, Florence
    Guyot, Patricia
    Chan, Keith
    Glowienka, Emily
    Konidaris, Gerasimos
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] BUDGET IMPACT ANALYSIS OF DABRAFENIB AND TRAMETINIB COMBINATION THERAPY IN THE TREATMENT OF BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER IN THE UNITED STATES
    Zhou, Z.
    Bensimon, A.
    Cheng, J.
    Dalal, A.
    VALUE IN HEALTH, 2017, 20 (09) : A422 - A422
1